Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intravitreal Triamcinolone and Biomarkers in Rhegmatogenous Retinal Detachment
Sponsor: Anggun Rama Yudantha
Summary
This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR). Participants are assigned to either an intervention group receiving a 2-mg intravitreal injection of TA 5-7 days before vitrectomy or a control group receiving standard surgical treatment. The study evaluates TGF-β2, TGF-β3, MMP-2, and MMP-9 levels in aqueous humor and vitreous, macrophage cell counts and inflammatory activity in vitreous, subretinal fluid optical density assessed by optical coherence tomography, and vessel diameter index assessed by optical coherence tomography angiography after surgery.
Official title: Effect of Intravitreal Triamcinolone Acetonide on TGF-β2, TGF-β3, and Matrix Metalloproteinase Levels in Patients With Rhegmatogenous Retinal Detachment: A Study of Aqueous Humor and Vitreous Biomarkers
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05-06
Completion Date
2026-03-18
Last Updated
2026-08-19
Healthy Volunteers
No
Interventions
Standard Vitrectomy
Participants underwent standard surgical treatment for rhegmatogenous retinal detachment with proliferative vitreoretinopathy without preoperative intravitreal triamcinolone acetonide.
Triamcinolone acetonide (TA)
Triamcinolone acetonide 2 mg was administered by intravitreal injection 5-7 days before vitrectomy.
Locations (1)
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta
Jakarta, DKI Jakarta, Indonesia